The study evaluated the efficacy and safety of ANX007 in patients with GA secondary to age-related macular degeneration. Credit: Dmitry Kalinovsky via Shutterstock.com.

Annexon has reported topline results from its ARCHER Phase II clinical trial of ANX007 for the treatment of patients with geographic atrophy (GA), a disease of vision loss.

The multi-centre, randomised, double-masked, sham-controlled ARCHER trial enrolled 270 patients to evaluate the efficacy and safety of ANX007 in patients with GA secondary to age-related macular degeneration.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Both female and male patients with foveal and non-foveal vision loss with an average age of 80 years were enrolled out of which 96% were from the US.

The study demonstrated a statistically significant, dose-dependent preservation of visual function during the 12-month treatment period.

Patients who received ANX007 monthly and every-other-month were protected against vision loss, as measured by changes from baseline in the functional endpoint of best corrected visual acuity.

Reduction in risk of 15-letter loss was observed in the monthly and in the every-other-month treated group of 72% and 48%, respectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The data support ANX007’s differentiated mechanism of action and represent the first demonstration of a complement-based therapy to protect against vision loss in the study.

However, the primary endpoint of mean rate of change in GA lesion area compared against sham over the 12-month period failed to reach statistical significance.

ANX007 was well tolerated in both monthly and every-other-month treated groups.

Annexon CEO Douglas Love said: “Based on the ARCHER trial results, we plan to engage with regulators to determine the optimal path forward to bring ANX007 to patients as expeditiously as possible.”